Castle Biosciences Inc (CSTL)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.04B
Last updated: Nov 17, 2026 at 11:05 AM ET
Castle Biosciences Inc (CSTL) Earnings: Report Dates and Results
Castle Biosciences (CSTL) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Castle Biosciences reported EPS of -$0.13, above the -$0.38 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CSTL has an expected report date of Feb 22, 2027.
CSTL Earnings Call
The latest CSTL earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 29 quarters below that had an estimate, CSTL beat 23, missed 5 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $102.89M, up 23.9% from $83.04M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.13 | -$0.38 | -$0.42 - -$0.25 | +65.79% | Beat | N/A | 10 | 2 up, 0 down | Nov 5, 2026 | $102.89M |
| Jun 30, 2026 | -$0.07 | -$0.44 | -$0.53 - -$0.30 | +84.09% | Beat | -146.7% | 9 | 2 up, 6 down | Jul 30, 2026 | $103.55M |
| Mar 31, 2026 | -$0.49 | -$0.49 | -$0.58 - -$0.29 | 0.00% | In line | N/A | 8 | N/A | May 6, 2026 | $83.68M |
| Dec 31, 2025 | -$0.08 | -$0.23 | -$0.38 - -$0.07 | +65.22% | Beat | -125.0% | 8 | 4 up, 0 down | Feb 26, 2026 | $87.01M |
| Sep 30, 2025 | -$0.02 | -$0.51 | -$0.65 - -$0.34 | +96.08% | Beat | -125.0% | 7 | 2 up, 0 down | Nov 3, 2025 | $83.04M |
| Jun 30, 2025 | $0.15 | -$0.50 | -$0.64 - -$0.36 | +130.00% | Beat | -51.6% | 7 | 0 up, 2 down | Aug 4, 2025 | $86.19M |
| Mar 31, 2025 | -$0.90 | -$0.07 | -$0.31 - $0.10 | N/A | N/A | N/A | 7 | 1 up, 1 down | May 5, 2025 | $87.99M |
| Dec 31, 2024 | $0.32 | $0.04 | -$0.12 - $0.16 | +700.00% | Beat | N/A | 7 | 2 up, 1 down | Feb 27, 2025 | $86.31M |
| Sep 30, 2024 | $0.08 | $0.01 | -$0.50 - $0.19 | +700.00% | Beat | N/A | 7 | 3 up, 0 down | Nov 4, 2024 | $85.78M |
| Jun 30, 2024 | $0.31 | -$0.24 | -$0.46 - -$0.10 | +229.17% | Beat | N/A | 9 | 1 up, 0 down | Aug 5, 2024 | $87.00M |
| Mar 31, 2024 | -$0.09 | -$0.31 | -$0.57 - -$0.17 | +70.97% | Beat | N/A | 9 | 0 up, 0 down | May 2, 2024 | $72.97M |
| Dec 31, 2023 | -$0.10 | -$0.54 | -$0.95 - -$0.17 | +81.48% | Beat | N/A | 8 | 2 up, 0 down | Feb 28, 2024 | $66.12M |
| Sep 30, 2023 | -$0.26 | -$0.73 | -$1.03 - -$0.47 | +64.38% | Beat | N/A | 8 | 0 up, 0 down | Nov 2, 2023 | $61.49M |
| Jun 30, 2023 | -$0.70 | -$0.91 | -$1.11 - -$0.67 | +23.08% | Beat | N/A | 8 | 0 up, 0 down | Aug 2, 2023 | $50.14M |
| Mar 31, 2023 | -$1.10 | -$0.89 | -$1.02 - -$0.74 | -23.60% | Miss | N/A | 8 | 0 up, 0 down | May 3, 2023 | $42.04M |
| Dec 31, 2022 | -$0.78 | -$0.84 | -$0.95 - -$0.78 | +7.14% | Beat | N/A | 8 | 1 up, 0 down | Feb 28, 2023 | $38.34M |
| Sep 30, 2022 | -$0.77 | -$0.97 | -$1.06 - -$0.41 | +20.62% | Beat | N/A | 7 | 0 up, 1 down | Nov 2, 2022 | $37.01M |
| Jun 30, 2022 | -$0.06 | -$0.80 | -$0.89 - -$0.52 | +92.50% | Beat | N/A | 7 | 1 up, 0 down | Aug 8, 2022 | $34.84M |
| Mar 31, 2022 | -$0.97 | -$0.74 | -$0.76 - -$0.57 | -31.08% | Miss | N/A | 7 | 0 up, 0 down | May 9, 2022 | $26.85M |
| Dec 31, 2021 | -$0.25 | -$0.47 | -$0.52 - -$0.39 | +46.81% | Beat | N/A | 7 | 0 up, 0 down | Feb 28, 2022 | $25.04M |
| Sep 30, 2021 | -$0.47 | -$0.37 | -$0.49 - -$0.32 | -27.03% | Miss | N/A | 6 | N/A | Nov 8, 2021 | $23.48M |
| Jun 30, 2021 | -$0.35 | -$0.39 | -$0.47 - -$0.27 | +10.26% | Beat | N/A | 5 | N/A | Aug 9, 2021 | $22.76M |
| Mar 31, 2021 | -$0.17 | -$0.18 | -$0.36 - -$0.18 | +5.56% | Beat | -666.7% | 6 | N/A | May 10, 2021 | $22.81M |
| Dec 31, 2020 | -$0.17 | -$0.12 | -$0.18 - -$0.05 | -41.67% | Miss | -254.5% | 5 | N/A | Mar 8, 2021 | $17.30M |
| Sep 30, 2020 | -$0.23 | -$0.15 | -$0.19 - $0.04 | -53.33% | Miss | -1250.0% | 4 | N/A | Nov 9, 2020 | $15.22M |
| Jun 30, 2020 | -$0.08 | -$0.44 | -$0.50 - -$0.26 | +81.82% | Beat | N/A | 4 | N/A | Aug 10, 2020 | $12.71M |
| Mar 31, 2020 | $0.03 | -$0.05 | -$0.24 - -$0.05 | +160.00% | Beat | N/A | 4 | N/A | May 11, 2020 | $17.42M |
| Dec 31, 2019 | $0.11 | -$0.20 | -$0.23 - -$0.18 | +155.00% | Beat | N/A | 3 | N/A | Mar 10, 2020 | $17.63M |
| Sep 30, 2019 | $0.02 | -$0.30 | -$0.31 - -$0.29 | +106.67% | Beat | N/A | 4 | N/A | Nov 11, 2019 | $14.77M |
| Jun 30, 2019 | -$1.05 | -$1.36 | -$3.07 - -$0.38 | +22.79% | Beat | N/A | 4 | N/A | Jul 26, 2019 | $10.74M |
| Mar 31, 2019 | -$1.22 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 29, 2019 | $8.72M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.85, after $0.62 the year before. It was -$2.14 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.85 | -237.1% |
| Dec 31, 2024 | $0.62 | N/A |
| Dec 31, 2023 | -$2.16 | N/A |
| Dec 31, 2022 | -$2.58 | N/A |
| Dec 31, 2021 | -$1.24 | N/A |
| Dec 31, 2020 | -$0.45 | N/A |
| Dec 31, 2019 | -$2.14 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,500 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,461 | 13 | |
| 2026Q2 | Jun 30, 2026 | 5,098 | 13 | |
| 2026Q1 | Mar 31, 2026 | 4,362 | 10 | |
| 2025Q4 | Dec 31, 2025 | 6,320 | 9 | |
| 2025Q3 | Sep 30, 2025 | 5,398 | 11 | |
| 2025Q2 | Jun 30, 2025 | 5,900 | 11 | |
| 2025Q1 | Mar 31, 2025 | 6,280 | 14 | |
| 2024Q4 | Dec 31, 2024 | 6,287 | 12 |
2026Q3 Earnings Call
Opening remarks
Camilla Zuckero Vice President, Investor Relations and Corporate Affairs Thank you, operator. Good afternoon, everyone. Welcome to Castle Biosciences Third Quarter 2026 Results Conference Call. Joining me today are Castle's Founder, President and Chief Executive Officer, Derek Maetzold, and Chief Financial Officer, Frank Stokes. Information recorded on this call speaks only as of today, November 5, 2026. Therefore, if you are listening to the replay or reading the transcript of this call, any time-sensitive information may no longer be accurate. A recording of today's call will be available on the Investor Relations page of the company's website for approximately three weeks following the conclusion of the call. Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements, including statements about expected addressable markets; statements containing projections regarding future events or our future financial or operational results and performance, including our anticipated 2026 total revenue, test report volume growth guidance and positive adjusted EBITDA for the fourth quarter, full year 2026 and full year 2027; and the impact of our investments in growth initiatives, including our ability to achieve long-term growth and drive stockholder value. Forward-looking statements are based upon current expectations and involve inherent risks and uncertainties, and there can be no assurances that the results contemplated in these statements will be realized. A number of factors and risks could cause actual results to differ materially from those contained in these forward-looking statements. Please refer to the risk factors in our most recent SEC filings for more information. These forward-looking statements speak only as of today, and we assume no obligation to update or revise these forward-looking statements as circumstances change. In addition, some of the information discussed today includes non-GAAP financial measures, such as adjusted revenue, adjusted gross margin and adjusted EBITDA, that have not been calculated in accordance with U.S. GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of our earnings release issued earlier today, which has been posted on the Investor Relations page of the company's website. I will now turn the call over to Derek.
Derek Maetzold Founder, President and Chief Executive Officer Thank you, Camilla, and good afternoon, everyone. Our team closed out a very successful third quarter, reflecting our focused execution and disciplined expense management, underscored by the clinical value our tests provide to clinicians and their patients. We delivered revenue of $102.9 million, 24% growth compared to the third quarter of 2025, primarily driven by TissueCypher test report volume, which grew by 47% compared to the third quarter of 2025.
Frequently Asked Questions About CSTL
When is Castle Biosciences's next earnings date?
Castle Biosciences's next earnings report is expected for Feb 22, 2027.
Did CSTL beat earnings estimates last quarter?
Yes. Castle Biosciences reported EPS of -$0.13 for the quarter ended Sep 30, 2026, above the -$0.38 estimate, a 65.79% surprise.
What EPS do analysts expect from CSTL next quarter?
The consensus EPS estimate for Castle Biosciences for the quarter ending Dec 31, 2026 is -$0.16 from 12 analysts, with estimates from -$0.39 to $0.00.
How often does CSTL beat earnings estimates?
Castle Biosciences beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +230.15%.
CSTL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts